symmetric dimethylarginine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
Studies (symmetric dimethylarginine) | Trials (symmetric dimethylarginine) | Recent Studies (post-2010) (symmetric dimethylarginine) | Studies ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Trials ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Recent Studies (post-2010) ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) |
---|---|---|---|---|---|
428 | 27 | 314 | 1,459 | 368 | 396 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abedini, S; Dahle, DO; Fellström, B; Holdaas, H; Holme, I; Jardine, A; März, W; Midtvedt, K; Mjøen, G; Pihlstrøm, H; Pilz, S | 1 |
1 trial(s) available for symmetric dimethylarginine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Article | Year |
---|---|
Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients.
Topics: Adult; Aged; Arginine; Biomarkers; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Graft Rejection; Humans; Indoles; Kidney; Kidney Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Time Factors; Transplant Recipients; Treatment Outcome | 2014 |